ProCE Banner Activity

CE / CME

Individualizing Initial HCV Therapy

Multimedia
Led by Tram T. Tran, MD, a panel of experts discusses their approach to individualizing initial HCV therapy based on key disease and patient characteristics that have an impact on treatment choice, including HCV genotype, race, cirrhosis, comorbidities, and comedications.

Pharmacists : 1.30 contact {hours} ({0.13} CEUs)

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: July 12, 2017

Expiration: July 11, 2018

No longer available for credit.

Share

Faculty

Kristen Marks

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Norah Terrault

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Tram T. Tran

Tram T. Tran, MD

Medical Director of Liver Transplant
Comprehensive Transplant Center
Cedars Sinai Medical Center
Associate Professor of Medicine
Division of Gastroenterology
Geffen UCLA School of Medicine
Los Angeles, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grants provided by

AbbVie

Bristol Myers Squibb

Gilead

Janssen

Merck & Co., Inc.

ViiV Healthcare

Target Audience

This program is intended for HCV specialists, infectious diseases clinicians, hepatologists, gastroenterologists, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with viral hepatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate the results of clinical studies of approved HCV treatments into optimized management strategies for both treatment-naive and DAA-experienced HCV-infected patients
  • Apply key guidelines and study data to ensure appropriate, individualized management for diverse patient populations with HCV and/or HBV infection, based on individual patient factors/comorbidities
  • Evaluate the impact of results of clinical studies of investigational treatments for chronic hepatitis C and B on future patient management strategies

Faculty Disclosure

Primary Author

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Kristen Marks, MD, has disclosed that she has received funds for research support (paid to her institution) from Bristol-Myers Squibb, Gilead Sciences, and Merck.

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD, FAASLD, AGAF, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and Merck and funds for research support from AbbVie.

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Biotest, Gilead Sciences, Merck, and Mylan Pharmaceuticals and funds for research support from AbbVie, Biotest, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Tram T. Tran, MD

Medical Director of Liver Transplant
Comprehensive Transplant Center
Cedars Sinai Medical Center
Associate Professor of Medicine
Division of Gastroenterology
Geffen UCLA School of Medicine
Los Angeles, California

Tram T. Tran, MD, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer Blanchette, PhD, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Credit Designation

This program is assigned ACPE Universal Activity #0797-9999-067-H01-P. This program is designated for up to 1.3 contact hours (0.13 CEUs) of continuing pharmacy education credit.

Type of Activity Application

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 12, 2017, through July 11, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in viral hepatitis management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.